FDA Approves First Topical Gene Therapy for Dystrophic Epidermolysis Bullosa Wounds
U.S. Food and Drug Administration
Around 65 percent of the wounds treated with Vyjuvek showed complete wound closure in DEB patients
Around 65 percent of the wounds treated with Vyjuvek showed complete wound closure in DEB patients
Unvaccinated individuals may receive a single dose of a bivalent vaccine, not multiple doses of the monovalent mRNA vaccines
“The price is not linked to the company’s performance, the price is linked to the value of the product,” says Stéphane Bancel, Moderna CEO